Lung Diseases Cies Search Engine [selected websites]

Loading

Blog Archive

Nov 19, 2007

MAP Pharmaceuticals, Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma

Oct 31, 2007 - ...MAP0005 is a combination of a corticosteroid and a long-acting beta2-agonist delivered to the respiratory tract using MAP Pharmaceuticals' Tempo(TM) inhaler. MAP0005 uses the Company's proprietary particle technology to combine the corticosteroid and beta-agonist components into a single drug particle in a fixed, pre-specified ratio. In addition, MAP Pharmaceuticals' technology allows for the particle structure to be specifically designed to target relevant areas in the lung and to release drug at a desired rate. MAP Pharmaceuticals believes that this approach may enable the reproducible and consistent administration of the two drugs in an optimal ratio simultaneously, and may provide improved safety and efficacy over currently available combination therapies for asthma and COPD... MAP Pharmaceuticals' Press Release -